Skip to main content

Table 1 Baseline characteristics of US-enrolled participants in the randomized trial of rATG versus basiliximab induction therapy

From: Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants

  rATG (n = 91) Basiliximab (n = 92) P
Recipient characteristics    
 Age (years), mean ± standard deviation 49.6 ± 12.4 49.0 ± 13.0 0.73
 Male, % 58 % 65 % 0.36
 Race, %:    0.29
  White 40 % 53 %  
  Black 45 % 40 %  
  Other 15 % 8 %  
 Peak panel-reactive antibody level,  mean ± standard deviation 18.7 ± 31.8 17.7 ± 30.7 0.83
Donor characteristics    
 Age (years), mean ± standard deviation 42.9 ± 16.3 43.4 ± 17.7 0.84
 Donors older than 50 years, % 44 % 47 % 0.77
 Male, % 49 % 58 % 0.30
 Race, %:    0.80
  White 79 % 80 %  
  Black 12 % 10 %  
  Other 9 % 10 %  
 Donation after cardiac death, % 7 % 7 % 0.99
 Diabetes mellitus, % 5 % 3 % 0.50
 Hypertension, % 30 % 26 % 0.62
Transplant characteristics    
 Cold ischemia time (hours), mean ± standard deviation 25.7 ± 9.6 26.0 ± 8.4 0.82
  Missing, % 8.8 % 7.6 % 0.77
 Previous transplantation, % 5 % 5 % 1.00
  1. From: N Engl J Med, Brennan DC and Schnitzler MA, Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction, Volume 359, Pages 1736–8, 2008. Massachusetts Medical Society [10]. Reprinted with permission